ZA907648B - Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias - Google Patents

Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias

Info

Publication number
ZA907648B
ZA907648B ZA907648A ZA907648A ZA907648B ZA 907648 B ZA907648 B ZA 907648B ZA 907648 A ZA907648 A ZA 907648A ZA 907648 A ZA907648 A ZA 907648A ZA 907648 B ZA907648 B ZA 907648B
Authority
ZA
South Africa
Prior art keywords
polypeptide
activity
leukaemias
human
treatment
Prior art date
Application number
ZA907648A
Other languages
English (en)
Inventor
Maud Brandely
Brandely Maud
Dominique Maraninchi
Maraninchi Dominique
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of ZA907648B publication Critical patent/ZA907648B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA907648A 1989-10-17 1990-09-25 Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias ZA907648B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8913546A FR2653020B1 (fr) 1989-10-17 1989-10-17 Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.

Publications (1)

Publication Number Publication Date
ZA907648B true ZA907648B (en) 1991-11-27

Family

ID=9386473

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA907648A ZA907648B (en) 1989-10-17 1990-09-25 Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias

Country Status (13)

Country Link
US (1) US5582822A (hu)
EP (1) EP0426521B1 (hu)
JP (1) JP2961189B2 (hu)
KR (1) KR0168420B1 (hu)
AT (1) ATE103494T1 (hu)
AU (1) AU640173B2 (hu)
CA (1) CA2027725A1 (hu)
DE (1) DE69007744T2 (hu)
DK (1) DK0426521T3 (hu)
FR (1) FR2653020B1 (hu)
HU (1) HU206048B (hu)
OA (1) OA09317A (hu)
ZA (1) ZA907648B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6852344B2 (en) * 2000-12-04 2005-02-08 Council Of Scientific And Industrial Research Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
GB2372598A (en) * 2001-02-26 2002-08-28 Coppereye Ltd Organising data in a database
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド アルブミン融合タンパク質
EP1511475B1 (en) * 2002-05-31 2005-10-05 Council of Scientific and Industrial Research A herbal molecule as potential anti-leukemic drug
US6967034B2 (en) * 2002-05-31 2005-11-22 Council Of Scientific And Industrial Research Herbal-based composition for treating acute and chronic myeloid leukemia
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2004024171A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7357652B1 (en) * 2006-10-27 2008-04-15 Leviton Manufacturing Company, Inc. Modular wiring system with locking elements
US8206920B2 (en) * 2007-03-26 2012-06-26 Arnold Ganser Diagnostic assay for the specific treatment of acute myeloid leukemia
US10622768B1 (en) 2019-05-10 2020-04-14 Walter Morgan Cowham Methods and systems for a modular plug-in bus wiring system
US10971879B1 (en) 2020-08-12 2021-04-06 Cowham Innovations, LLC. Electrical connection forming tool
CN111821423B (zh) * 2020-08-17 2023-04-11 中南大学湘雅二医院 一种白介素2用于治疗慢性自发性荨麻疹的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins

Also Published As

Publication number Publication date
EP0426521B1 (fr) 1994-03-30
HUT55241A (en) 1991-05-28
HU206048B (en) 1992-08-28
CA2027725A1 (fr) 1991-04-18
OA09317A (fr) 1992-09-15
HU906463D0 (en) 1991-04-29
FR2653020A1 (fr) 1991-04-19
DE69007744D1 (de) 1994-05-05
EP0426521A1 (fr) 1991-05-08
JPH03193736A (ja) 1991-08-23
KR910007541A (ko) 1991-05-30
US5582822A (en) 1996-12-10
JP2961189B2 (ja) 1999-10-12
KR0168420B1 (ko) 1999-01-15
FR2653020B1 (fr) 1993-03-26
DE69007744T2 (de) 1994-07-28
AU640173B2 (en) 1993-08-19
ATE103494T1 (de) 1994-04-15
AU6466790A (en) 1991-04-26
DK0426521T3 (da) 1994-05-02

Similar Documents

Publication Publication Date Title
ZA907648B (en) Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
EP0433827A3 (en) Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto
HK65693A (en) Pharmaceutical composition containing a human granulocyte colony stimulating factor for the treatment of leukopenia
IL102346A0 (en) Cysteine depleted il-6 muteins
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
ZA904353B (en) Use of a polypeptide having the activity of human interleukin 2 for preparing a pharmaceutical composition intended for the treatment of primary cancers of the pleura
IL89662A0 (en) Pharmaceutical compositions comprising interferon-beta 1
IE871358L (en) Interferon for carcinoma
ZA919682B (en) Use of a polypeptide having human interleukin 2 activity for the preparation of pharmaceutical compositions for the treatment of pneumothorax
IL96229A0 (en) Use of a polypeptide having the activity of gamma interferon for the preparation of pharmaceutical compositions intended for the treatment of primary cancers of the pleura
HU900202D0 (en) Process for manufacturing of pharmaceutical compositions comprising gamma-interferon suitable to treatment of ovarion cancer